{
  "id": 15754116,
  "title": "STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more",
  "url": "https://urgent.news/2026/10/20/stat-pharmalittle-were-reading-about-drug-launch-prices-an",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-20T14:02:16.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/10/20/drug-launch-prices-rose-astrazeneca-ai-deal/"
  },
  "original_language": "en",
  "account": "Good morning, and welcome to another bustling day at the Pharmalot campus. As the sun rises over the horizon, a clear blue sky and gentle breezes greet us, setting a pleasant atmosphere for our daily briefing. Our trusty kettle is ready to brew a soothing cup of peppermint mocha, inviting you to join us for the full experience. We've also prepared some replicas for those who wish to delve deeper into today's topics. As always, we welcome your feedback, criticism, and tips in the comments section.\n\nIn light of persistent concerns surrounding prescription drug prices, a recent analysis by the Institute for Clinical and Economic Review and West Health reveals a concerning trend. The median net price for 202 newly launched medicines, when adjusted for inflation and manufacturer discounts, surged by 35% to $257,000 in 2025 from $190,000 in 2022. A staggering one in four drugs launched in 2025 exceeded an annual net price of $500,000, while another 34% fell within the range of $200,000 to $500,000. However, it's worth noting that the most significant increase in net launch prices took place between 2022 and 2023, with a 2% decline observed in 2023.\n\nNovo Nordisk's experimental drug, CagriSema, aims to address the weight loss market's decline, which has been attributed to patent expirations of Novo's blockbuster weight loss medication, Wegovy. In a late-stage study, CagriSema demonstrated a 25% average weight loss in women with obesity or overweight after 68 weeks, compared to 3% weight loss in women on a placebo. The full trial, involving over 3,400 adults, resulted in an average weight loss of 22.7%, slightly below the targeted 25%.",
  "summary": "The median net price for newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% from 2022 to 2025.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}